The Lighthouse | vascepa

Currently viewing the tag: "vascepa"

Amarin Manipulation and Opportunity

By Erik Zimerman On June 25, 2013 · Add Comment · In Avvisi, The Whiskey Room

Amarin Corporation (AMRN), a pharmaceutical company that is currently marketing the recently approved Vascepa, is being offered at an almost outlandishly low share price. As the article is being written, Amarin (AMRN) is down around the 5.30’s, far below its previous 52-week low (before FDA approval). It is clear that short of some lurking, largely unknown phenomenon, Amarin has fallen prey to manipulation. Not implying any illegality, due to its infancy, and relatively small float, bear raids have been repeatedly successful in driving down the stock price, especially along with media “pieces” from the same circle of authors that continuously seem to push a curiously negative agenda surrounding the company and fall quite short of accurate or insightful. Currently, with a lull in big headlines and possible catalysts, the bear interest has succeeded in greatly depreciating the stock price, as the avalanche took with it retail investors that have despaired, given up, or were simply forced to sell due to margin calls as the stock price plummeted. The point of true success for any bear raid, is when the price fall gathers momentum on continues on by itself; this is when true profit is possible, as the bear raiders can [...]

[Continue Reading...]

Lighthouse Stock Tip Update – Amarin Script Sales

By Erik Zimerman On March 7, 2013 · 7 Comments · In The Whiskey Room

A few months back, one of my updates suggested CEL and AMRN as short term/medium term investments. In the case of CEL, the market had overreacted to new competition in the Israeli market and investors with our suggested timing were repaid with an approximate 69% return. In Amarin’s case (Amarin Corporation Plc, NASDAQ: AMRN), though the stock continued to rise after our endorsement, and providing a 30% return shorty thereafter, I suggested holding on to this position still further. Since Amarin’s announcement to “Go it Alone” in launching their Marine indication for Vascepa, and continuous FDA delays in reaching a regulatory exclusivity decision (NCE), Amarin has continued to lose value; now well below our suggested entry point. Some decrease, based on the the uncertainty of smaller companies launching new drugs successively and lack of acquisition or marketing partner (did they know something we did not? or was the CEO simply holding for too high a bid?) was quite logical. In fact, merger speculation had largely helped fuel Amarin’s rapid increase in share price. Though management so far seems to have been more than competent in achieving their goals and milestones they did fail miserably during this period of rapid share value loss in communicating with their investors. This gave fuel [...]

[Continue Reading...]

Amarin “Hostile” Takeover

By Erik Zimerman On December 21, 2012 · 2 Comments · In The Whiskey Room

Background Amarin (AMRN) is an Irish based company with a recently FDA approved drug called Vascepa with very large market potential. Vascepa is broadly a prescription grade Omega 3 fatty acid (like those found in fish oils) based on highly purified EPA . Currently, the only other similar FDA approved drug comparable to Vascepa is Lovaza. Lovaza has reached annual sales of nearly $1 billion. Vascepa has several advantages over Lovaza, most importantly that it does not raise LDLs and in many cases lowers them. As far as market potential, Vascepa has a huge advantage over Lovaza. Lovaza was approved only for patients with very high triglycerides (>500 mg/dl) while Vascepa’s ANCHOR study shows that it is also effective for patients with high triglycerides (>200 mg/dl), and is on track to receive this label indication as well. The significance of this difference is hard to overstate. Lovaza’s prescription market population in the US is restricted to about 5 million Americans with very high triglycerides (which does not prevent it from selling $1 billion annually) while the US population with high triglycerides is 10 times that amount, at about 50 million. Though it should not be assumed that these two populations would purchase prescription drugs at the same rate, this fact alone makes [...]

[Continue Reading...]

The Lighthouse Stock Tips – Amarin and Cellcom

By Erik Zimerman On July 31, 2012 · 4 Comments · In Avvisi, The Whiskey Room

[Continue Reading...]

- English
- עברית
Recent Posts
Top Posts & Pages
Tags
2012 election 2016 US presidential election 2019 Israeli Elections anti-Israel bias Appeasement arab spring Avigdor Lieberman Barak H Obama Benjamin Netanyahu bias media Bibi Donald Trump Egypt election 2016 elections Gaza Gaza Strip George W Bush GOP Hamas hillary clinton Hosni Mubarak IDF Iran Islamic Jihad Islamists Israel Israeli Knesset liberal media liberals Libya Likud media bias Mitt Romney Mohammed Morsi Muslim Brotherhood Muslim Terror Naftali Bennett NATO Newt Gingrich Qaddafi select Sinai Syria terrorism
Halls
Archives
April 2024

S M T W T F S

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30

« Nov
Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Amarin Manipulation and Opportunity

Lighthouse Stock Tip Update – Amarin Script Sales

Amarin “Hostile” Takeover

The Lighthouse Stock Tips – Amarin and Cellcom

Recent Posts

Top Posts & Pages

Tags

Halls

Archives

Subscribe to Blog via Email